Abstract | PURPOSE: The in vivo antitumor activity of a novel topoisomerase I inhibitor, J-107088, was tested in athymic nude mice bearing subcutaneous or intracranial pediatric and adult malignant CNS tumor-derived xenografts. METHODS: RESULTS:
J-107088 produced regressions and significant growth inhibition in all five of the xenograft lines growing subcutaneously. Growth delays ranged from 7.6 days with D-245 MG to 62.1 days with D-456 MG (P < 0.001). J-107088 also produced an 83% increase in survival in mice bearing intracranial D-456 MG (P < 0.001). CONCLUSION: These results indicate that J-107088 may be active in the treatment of childhood and adult malignant brain tumors and provide the rationale for initiation of clinical trials with this agent.
|
Authors | C M Cavazos, S T Keir, T Yoshinari, D D Bigner, H S Friedman |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 48
Issue 3
Pg. 250-4
(Sep 2001)
ISSN: 0344-5704 [Print] Germany |
PMID | 11592348
(Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Carbazoles
- Enzyme Inhibitors
- Glucosides
- Indoles
- Topoisomerase I Inhibitors
- edotecarin
|
Topics |
- Adult
- Animals
- Antineoplastic Agents
(therapeutic use)
- Brain Neoplasms
(drug therapy)
- Carbazoles
(therapeutic use)
- Child
- Enzyme Inhibitors
(therapeutic use)
- Female
- Glioma
(drug therapy)
- Glucosides
(therapeutic use)
- Humans
- Indoles
- Injections, Intraperitoneal
- Injections, Subcutaneous
- Male
- Mice
- Mice, Nude
- Neoplasm Transplantation
- Survival Rate
- Topoisomerase I Inhibitors
- Transplantation, Heterologous
- Treatment Outcome
- Tumor Cells, Cultured
|